...
首页> 外文期刊>Journal of Medicinal Chemistry >Novel Benzazole Derivatives Endowed with Potent Antiheparanase Activity
【24h】

Novel Benzazole Derivatives Endowed with Potent Antiheparanase Activity

机译:新的苯并唑衍生物赋予有效的抗亲氨酸酶活性

获取原文
获取原文并翻译 | 示例
           

摘要

Heparanase is the sole mammalian enzyme capable of cleaving glycosaminoglycan heparan sulfate side chains of heparan sulfate proteoglycans. Its altered activity is intimately associated with tumor growth, angiogenesis, and metastasis. Thus, its implication in cancer progression makes it an attractive target in anticancer therapy. Herein, we describe the design, synthesis, and biological evaluation of new benzazoles as heparanase inhibitors. Most of the designed derivatives were active at micromolar or submicromolar concentration, and the most promising compounds are fluorinated and/or amino acids derivatives 13a, 14d, and 15 that showed IC50 0.16-0.82 mu M. Molecular docking studies were performed to rationalize their interaction with the enzyme catalytic site. Importantly, invasion assay confirmed the antimetastatic potential of compounds 14d and 15. Consistently with its ability to inhibit heparanase, compound 15 proved to decrease expression of genes encoding for proangiogenic factors such as MMP-9, VEGF, and FGFs in tumor cells.
机译:乙酰乙肝酶是能够切割糖胺聚糖硫酸乙酰肝素硫酸乙酰丙酯蛋白聚糖的硫代氨酰硫酸盐侧链的唯一哺乳动物酶。其改变的活性与肿瘤生长,血管生成和转移密切相关。因此,其对癌症进展的含义使其成为抗癌疗法的有吸引力的靶标。在此,我们描述了新苯并唑的设计,合成和生物学评估为乙酰肝素酶抑制剂。大多数设计的衍生物在微摩尔或亚亚摩尔粒子浓度下活跃,最有希望的化合物是氟化和/或氨基酸衍生物13a,14d和15,显示IC50 0.16-0.82 mu m.进行分子对接研究以合理化它们的相互作用用酶催化部位。重要的是,侵袭测定证实了化合物14D和15的抗致致动潜力。始终如一的抑制乙酰肝素酶的能力,化合物15证明是为了降低肿瘤细胞中MMP-9,VEGF和FGF等常致生成因子的基因的表达。

著录项

  • 来源
    《Journal of Medicinal Chemistry》 |2018年第15期|共19页
  • 作者单位

    Sapienza Univ Roma Ist Pasteur Fdn Cenci Bolognetti Dipartimento Chim &

    Tecnol Farmaco Ple Aldo Moro 5 I-00185 Rome Italy;

    Sapienza Univ Roma Ist Pasteur Fdn Cenci Bolognetti Dipartimento Chim &

    Tecnol Farmaco Ple Aldo Moro 5 I-00185 Rome Italy;

    Sapienza Univ Roma Ist Pasteur Fdn Cenci Bolognetti Dipartimento Chim &

    Tecnol Farmaco Ple Aldo Moro 5 I-00185 Rome Italy;

    Sapienza Univ Roma Ist Pasteur Fdn Cenci Bolognetti Dipartimento Chim &

    Tecnol Farmaco Ple Aldo Moro 5 I-00185 Rome Italy;

    Sapienza Univ Roma Ist Pasteur Fdn Cenci Bolognetti Dipartimento Chim &

    Tecnol Farmaco Ple Aldo Moro 5 I-00185 Rome Italy;

    Sapienza Univ Roma Ist Pasteur Fdn Cenci Bolognetti Dipartimento Chim &

    Tecnol Farmaco Ple Aldo Moro 5 I-00185 Rome Italy;

    Sapienza Univ Roma Ist Pasteur Fdn Cenci Bolognetti Dipartimento Chim &

    Tecnol Farmaco Ple Aldo Moro 5 I-00185 Rome Italy;

    Sapienza Univ Roma Ist Pasteur Fdn Cenci Bolognetti Dipartimento Chim &

    Tecnol Farmaco Ple Aldo Moro 5 I-00185 Rome Italy;

    Sapienza Univ Roma Ist Pasteur Fdn Cenci Bolognetti Dipartimento Chim &

    Tecnol Farmaco Ple Aldo Moro 5 I-00185 Rome Italy;

    Univ Parma Dipartimento Sci Alimenti &

    Farmaco Parco Area Sci 27-A I-43124 Parma Italy;

    Univ Parma Dipartimento Sci Alimenti &

    Farmaco Parco Area Sci 27-A I-43124 Parma Italy;

    Univ Parma Dipartimento Sci Alimenti &

    Farmaco Parco Area Sci 27-A I-43124 Parma Italy;

    Takis Sr1 Via Castel Romano 100 I-00128 Rome Italy;

    Takis Sr1 Via Castel Romano 100 I-00128 Rome Italy;

    Takis Sr1 Via Castel Romano 100 I-00128 Rome Italy;

    Fdn IRCCS Ist Nazl Tumori Unita Farmacol Mol Dipartimento Ric Appl &

    Sviluppo Tecnol Via Amadeo 42 I-20133 Milan Italy;

    R&

    D Alfasigma SpA Via Pontina Km 30 400 I-00071 Rome Italy;

    R&

    D Alfasigma SpA Via Pontina Km 30 400 I-00071 Rome Italy;

    Sapienza Univ Roma Ist Pasteur Fdn Cenci Bolognetti Dipartimento Chim &

    Tecnol Farmaco Ple Aldo Moro 5 I-00185 Rome Italy;

    R&

    D Alfasigma SpA Via Pontina Km 30 400 I-00071 Rome Italy;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号